Prophylaxis of post-ERCP pancreatitis by the intravenous administration of the non-steroidal anti-inflammatory drug
Not Applicable
Recruiting
- Conditions
- Post-ERCP pancreatitis
- Registration Number
- JPRN-UMIN000013193
- Lead Sponsor
- Division of Gastroenterology and Hepatology, Department of Medicine,Nihon University School of Medicine, Tokyo, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
The following patients were excluded: those with contraindications to flurbiprofen axetil, those who had taken any NSAID during the preceding week, those diagnosed with acute pancreatitis during the month before ERCP, those with an anticipated low risk of PEP (those with chronic calcific pancreatitis or a pancreatic head tumor or those undergoing routine biliary stent exchange), and those who did not agree to participate in the study.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary outcome is reduction in the rate of post-ERCP pancreatitis, defined as new upper abdominal pain and hyperamylasemia.
- Secondary Outcome Measures
Name Time Method Secondary outcomes included prevention of increase in post-ERCP serum amylase levels and reduction in the severity of PEP.